A class action lawsuit has been filed against Jazz Pharmaceuticals regarding its narcolepsy drug, Xyrem [1]. The lawsuit, filed in the U.S. District Court for the District of Delaware, accuses the company of engaging in a "product hopping" scheme to illegally extend its monopoly on the drug [1].
What is "Product Hopping"?
Product hopping, also known as "evergreening" or "product switching," is a strategy where a pharmaceutical company makes minor changes to an existing drug and markets it as a new product. This can be done to extend patent protection and delay the entry of generic competition [2]. In the case of Xyrem, the lawsuit alleges Jazz Pharmaceuticals introduced a reformulated version, Xywav, which contains the same active ingredient but with different salt forms [1].
Why is Jazz Pharmaceuticals Being Sued Over Xyrem?
The class action lawsuit claims Jazz Pharmaceuticals engaged in anticompetitive practices by promoting the reformulated Xywav as superior to the original Xyrem [1]. Plaintiffs allege that Jazz phased out the older formulation, Xyrem, and pressured doctors and patients to switch to Xywav, thereby extending Xyrem's market exclusivity beyond its original patent life and delaying the availability of lower-cost generic versions of Xyrem [1]. This tactic, the lawsuit argues, violates antitrust laws by preventing fair competition.
What are the Allegations in the Lawsuit?
The lawsuit's core allegations include:
* Anticompetitive Conduct: Jazz Pharmaceuticals is accused of orchestrating a scheme to unlawfully maintain its monopoly over Xyrem [1].
* Product Hopping: The introduction and promotion of Xywav are central to the claim that Jazz engaged in product hopping to extend its market exclusivity [1].
* Illegal Monopoly Extension: The lawsuit contends that Jazz's actions prevented generic versions of Xyrem from entering the market and offering more affordable treatment options [1].
* Harm to Consumers: The plaintiffs argue that these actions have harmed patients by forcing them to continue using a branded drug with limited competition, likely at higher prices [1].
When Could Generic Xyrem Become Available?
The patent landscape for Xyrem and Xywav is complex. While patents for the original Xyrem have expired, Jazz Pharmaceuticals has obtained new patents for Xywav [3]. The success of the current class action lawsuit could impact the timeline for generic entry of the original Xyrem formulation, potentially leading to earlier availability if the "product hopping" allegations are substantiated [1]. Information on specific patent expiry dates and potential generic competition can often be tracked through resources like DrugPatentWatch.com [3].
What is the Difference Between Xyrem and Xywav?
Both Xyrem and Xywav are prescribed for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years of age and older with narcolepsy [1]. The key difference lies in their formulation. Xyrem contains sodium oxybate, while Xywav contains calcium, magnesium, potassium, and sodium oxybates. Despite the different salt forms, both drugs contain oxybate as the active pharmaceutical ingredient [1]. The lawsuit centers on the argument that this reformulation was primarily a strategy to extend market exclusivity rather than a significant therapeutic advancement.